This report provides updated results of overall survival, disease-free survival, and distant relapse-free survival in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk, early breast cancer. The study involved a group of 5,637 patients who were randomly divided into two groups. One cohort received abemaciclib plus endocrine therapy, with the other cohort assigned endocrine therapy alone. Results indicated that although abemaciclib did reduce the risk of recurrence, further research would be needed to determine if overall survival is improved by the use of abemaciclib plus endocrine therapy in this population.

Reference: Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77-90. doi:10.1016/S1470-2045(22)00694-5